Published in Biochem Biophys Res Commun on September 16, 1980
Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A (1981) 3.42
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci U S A (1984) 2.06
Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A (1983) 1.91
The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol (2009) 1.88
Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax (1984) 1.71
Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest (1984) 1.65
IgE-mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells. J Exp Med (1983) 1.56
Interconversion of leukotrienes catalyzed by purified gamma-glutamyl transpeptidase: concomitant formation of leukotriene D4 and gamma-glutamyl amino acids. Proc Natl Acad Sci U S A (1982) 1.52
Radioimmunoassay of the leukotrienes of slow reacting substance of anaphylaxis. Proc Natl Acad Sci U S A (1981) 1.45
Functional characterization of synthetic leukotriene B and its stereochemical isomers. J Exp Med (1981) 1.37
Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A (2008) 1.33
Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci U S A (1984) 1.32
Generation of leukotriene C4 from a subclass of mast cells differentiated in vitro from mouse bone marrow. Proc Natl Acad Sci U S A (1982) 1.30
Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci U S A (2004) 1.30
Oxidative inactivation of leukotriene C4 by stimulated human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1982) 1.22
Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem (2013) 1.22
Recombinant human tumour necrosis factor (rTNF)2 enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the Ca2+ ionophore A23187. Clin Exp Immunol (1987) 1.21
Leukotrienes in inflammation. Agents Actions (1986) 1.20
The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am J Pathol (1987) 1.18
Characterization of a leukotriene D4 receptor in guinea pig lung. Proc Natl Acad Sci U S A (1983) 1.14
Contractile activities of structural analogs of leukotrienes C and D: role of the polar substituents. Proc Natl Acad Sci U S A (1981) 1.14
Bioconversion of C-6 sulfidopeptide leukotrienes by the responding guinea pig ileum determines the time course of its contraction. J Clin Invest (1983) 1.06
Radioimmunoassay for leukotriene B4. Proc Natl Acad Sci U S A (1982) 1.05
Contractile activities of structural analogs of leukotrienes C and D: necessity of a hydrophobic region. Proc Natl Acad Sci U S A (1981) 1.02
Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells. Proc Natl Acad Sci U S A (1986) 1.00
The mechanism of LTE4-induced histamine hyperresponsiveness in guinea-pig tracheal and human bronchial smooth muscle, in vitro. Br J Pharmacol (1991) 0.94
Specific receptors for leukotriene C4 on a smooth muscle cell line. J Clin Invest (1983) 0.93
Slow reacting substances (leukotrienes): enzymes involved in their biosynthesis. Proc Natl Acad Sci U S A (1982) 0.92
Identification and characterization of a monocyte-derived neutrophil-activating factor in corticosteroid-resistant bronchial asthma. J Clin Invest (1989) 0.91
The effect of indomethacin on the contractile response of the guinea-pig lung parenchymal strip to leukotrienes B4, C4, D4 and E4. Br J Pharmacol (1983) 0.86
The contractile activities of lipoxin A4 and lipoxin B4 for guinea-pig airway tissues. Br J Pharmacol (1988) 0.83
Specificity and cellular distribution of human polymorphonuclear leucocyte receptors for leukotriene C4. Immunology (1987) 0.80
Specific binding of leukotriene C4 to ileal segments and subcellular fractions of ileal smooth muscle cells. Proc Natl Acad Sci U S A (1984) 0.77
L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man. Br J Clin Pharmacol (1989) 0.77
The effect of epithelium removal on leukotriene E4-induced histamine hyperresponsiveness in guinea-pig tracheal smooth muscle. Br J Pharmacol (1992) 0.76
Release of leukotrienes C (LTC) and D (LTD) from inflammatory macrophages during phagocytosis of zymosan and bacteria. Agents Actions (1981) 0.75
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet (1997) 10.93
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
CARBOHYDRATE METABOLISM IN ADDISON'S DISEASE. J Clin Invest (1940) 9.89
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Sponsorship, authorship, and accountability. Lancet (2001) 7.10
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Sponsorship, authorship, and accountability. N Engl J Med (2001) 6.20
Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science (1997) 6.00
Sponsorship, authorship and accountability. CMAJ (2001) 5.86
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science (2001) 5.22
Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci U S A (1999) 5.08
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 3.84
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med (1998) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature (2000) 3.61
Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA (1998) 3.57
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
THE EFFECT OF 17-HYDROXYCORTICOSTERONE AND RELATED ADRENAL CORTICAL STEROIDS ON SODIUM AND CHLORIDE EXCRETION. Science (1941) 3.45
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
Triggering myocardial infarction by marijuana. Circulation (2001) 3.36
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA (2001) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
The complement system of man. I. N Engl J Med (1972) 3.09
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat (2001) 3.07
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Molecular genetics of human blue cone monochromacy. Science (1989) 2.92
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol (1988) 2.91
The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med (1994) 2.90
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat (2003) 2.75
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet (1994) 2.72
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
Sponsorship, authorship, and accountability. Ann Intern Med (2001) 2.66
Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem (1998) 2.66
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol (1985) (1988) 2.64
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature (1992) 2.64
Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A (1993) 2.64
Appraising Public Medical Services. Am J Public Health Nations Health (1941) 2.62
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
An information processing model of anxiety: automatic and strategic processes. Behav Res Ther (1997) 2.55
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
Amelioration of chronic ileitis by nitric oxide synthase inhibition. J Pharmacol Exp Ther (1993) 2.54
Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. Nat Genet (2000) 2.53
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A (1994) 2.41
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
The cardiac donor. Surg Gynecol Obstet (1971) 2.39
Infectious complications after cardiac transplantation in man. Ann Intern Med (1971) 2.37